Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa | Global Health | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
1.
Grinsztejn  B, Hosseinipour  MC, Ribaudo  HJ,  et al; HPTN 052-ACTG Study Team.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.  Lancet Infect Dis. 2014;14(4):281-290.PubMedGoogle ScholarCrossref
2.
Cohen  MS, Chen  YQ, McCauley  M,  et al; HPTN 052 Study Team.  Prevention of HIV-1 infection with early antiretroviral therapy.  N Engl J Med. 2011;365(6):493-505.PubMedGoogle ScholarCrossref
3.
Lundgren  JD, Babiker  AG, Gordin  F,  et al; INSIGHT START Study Group.  Initiation of antiretroviral therapy in early asymptomatic HIV infection.  N Engl J Med. 2015;373(9):795-807.PubMedGoogle ScholarCrossref
4.
Granich  RM, Gilks  CF, Dye  C, De Cock  KM, Williams  BG.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.  Lancet. 2009;373(9657):48-57.PubMedGoogle ScholarCrossref
5.
Walensky  RP, Borre  ED, Bekker  LG,  et al.  The anticipated clinical and economic effects of 90-90-90 in South Africa.  Ann Intern Med. 2016;165(5):325-333.PubMedGoogle ScholarCrossref
6.
Tanser  F, Bärnighausen  T, Grapsa  E, Zaidi  J, Newell  ML.  High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.  Science. 2013;339(6122):966-971.PubMedGoogle ScholarCrossref
7.
Stover  J, Hallett  TB, Wu  Z,  et al; New Prevention Technology Study Group.  How can we get close to zero? the potential contribution of biomedical prevention and the investment framework towards an effective response to HIV.  PLoS One. 2014;9(11):e111956.PubMedGoogle ScholarCrossref
8.
UNAIDS.  90-90-90: An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed May 8, 2017.
9.
WHO.  Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What’s New: November 2015. Geneva, Switzerland: World Health Organization; 2015.
10.
Gaolathe  T, Wirth  KE, Holme  MP,  et al; Botswana Combination Prevention Project study team.  Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.  Lancet HIV. 2016;3(5):e221-e230.PubMedGoogle ScholarCrossref
11.
Levi  J, Raymond  A, Pozniak  A, Vernazza  PL, Kohler  P, Hill  A.  Can the UNAIDS 90–90–90 target be reached? a systematic analysis of national HIV treatment cascades.  BMJ Global Health. 2016; 1(2):e000010. doi:10.1136/bmjgh-2015-000010Google ScholarCrossref
12.
Granich  R, Gupta  S, Hall  I, Aberle-Grasse  J, Hader  S, Mermin  JEgger  M.  Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review.  PLoS Med. 2017;14(4):e1002253.PubMedGoogle ScholarCrossref
13.
Cherutich  P, Kim  AA, Kellogg  TA,  et al.  Detectable HIV viral load in Kenya: data from a population-based survey.  PLoS One. 2016;11(5):e0154318.PubMedGoogle ScholarCrossref
14.
Adakun  SA, Siedner  MJ, Muzoora  C,  et al.  Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda.  J Acquir Immune Defic Syndr. 2013;62(3):317-321.PubMedGoogle ScholarCrossref
15.
Tenthani  L, Haas  AD, Tweya  H,  et al; Ministry of Health in Malawi and IeDEA Southern Africa.  Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (Option B+) in Malawi.  AIDS. 2014;28(4):589-598.PubMedGoogle ScholarCrossref
16.
Chamie  G, Clark  TD, Kabami  J,  et al.  A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study.  Lancet HIV. 2016;3(3):e111-e119.PubMedGoogle ScholarCrossref
17.
Ayieko  J, Van Rie  A, Owaraganise  A,  et al. A novel strategy for accelerated linkage to care following community-wide HIV testing. Poster presented at: International AIDS Conference; July 18-22, 2016; Durban, South Africa.
18.
Kwarisiima  D, Jain  V, Owaraganise  A,  et al. Virologic efficacy, safety, and retention in adults starting ART at high CD4 with streamlined care in rural Africa. Oral presentation at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
19.
Jain  V, Liegler  T, Kabami  J,  et al; SEARCH Collaboration.  Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.  Clin Infect Dis. 2013;56(4):598-605.PubMedGoogle ScholarCrossref
20.
Balzer  L, Schwab  J, van der Laan  M, Petersen  M. Evaluation of progress towards the UNAIDS 90-90-90 HIV care cascade: a description of statistical methods used in an interim analysis of the intervention communities in the SEARCH Study. http://biostats.bepress.com/cgi/viewcontent.cgi?article=1365&context=ucbbiostat. Accessed May 8, 2017.
21.
van der Laan  MJ, Gruber  S.  Targeted minimum loss based estimation of causal effects of multiple time point interventions.  Int J Biostat. 2012;8(1):8.PubMedGoogle ScholarCrossref
22.
van der Laan  MJ, Polley  EC, Hubbard  AE.  Super learner.  Stat Appl Genet Mol Biol. 2007;6:e25.PubMedGoogle ScholarCrossref
23.
Polley  EC, van der Laan  M.  SuperLearner: super learner prediction: R package, version 2.0-21. http://cran.r-project.org/web/packages/SuperLearner/index.html. Accessed May 8, 2017.
24.
R Core Team.  R: a language and environment for statistical computing. http://www.R-project.org/. Accessed May 8, 2017.
25.
Schwab  J, Lendle  S, Petersen  M, Gruber  S, van der Laan  M.  ltmle: Longitudinal targeted maximum likelihood estimation. http://cran.r-project.org/web/packages/ltmle/. Accessed May 8, 2017.
26.
Jain  V, Petersen  ML, Liegler  T,  et al; SEARCH Collaboration.  Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis.  Lancet HIV. 2017;4(3):e122-e133.PubMedGoogle ScholarCrossref
27.
Losina  E, Bassett  IV, Giddy  J,  et al.  The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa.  PLoS One. 2010;5(3):e9538.PubMedGoogle ScholarCrossref
28.
Geng  EH, Odeny  TA, Lyamuya  R,  et al; East Africa International Epidemiologic Databases to Evaluate AIDS Consortium.  Retention in care and patient-reported reasons for undocumented transfer or stopping care among HIV-infected patients on antiretroviral therapy in Eastern Africa: application of a sampling-based approach.  Clin Infect Dis. 2016;62(7):935-944.PubMedGoogle ScholarCrossref
29.
Henry J. Kaiser Family Foundation.  Financing the response to AIDS in low- and middle-income countries: international assistance from donor governments in 2014. https://kaiserfamilyfoundation.files.wordpress.com/2015/06/7347-11-financing-the-response-to-aids-in-low-and-middle-income-countries.pdf. Accessed May 8, 2017.
30.
Hodgson  I, Plummer  ML, Konopka  SN,  et al.  A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women.  PLoS One. 2014;9(11):e111421.PubMedGoogle ScholarCrossref
31.
Treves-Kagan  S, Steward  WT, Ntswane  L,  et al.  Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa.  BMC Public Health. 2016;16:87.PubMedGoogle ScholarCrossref
32.
Kranzer  K, Lawn  SD, Johnson  LF, Bekker  LG, Wood  R.  Community viral load and CD4 count distribution among people living with HIV in a South African township: implications for treatment as prevention.  J Acquir Immune Defic Syndr. 2013;63(4):498-505.PubMedGoogle ScholarCrossref
33.
Maman  D, Zeh  C, Mukui  I,  et al.  Cascade of HIV care and population viral suppression in a high-burden region of Kenya.  AIDS. 2015;29(12):1557-1565.PubMedGoogle ScholarCrossref
34.
Lippman  SA, Shade  SB, El Ayadi  AM,  et al.  Attrition and opportunities along the HIV care continuum: findings from a population-based sample, North West Province, South Africa.  J Acquir Immune Defic Syndr. 2016;73(1):91-99.PubMedGoogle ScholarCrossref
35.
Maman  D, Chilima  B, Masiku  C,  et al.  Closer to 90-90-90: the cascade of care after 10 years of ART scale-up in rural Malawi: a population study.  J Int AIDS Soc. 2016;19(1):20673.PubMedGoogle ScholarCrossref
36.
Justman  J, Hoos  D, Kalton  G,  et al. 114LB: Real progress in the HIV epidemic: PHIA findings from Zimbabwe, Malawi, and Zambia. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, WA.
37.
Grabowski  M, Nakigozi  G, Nalugoda  F,  et al. 34LB Combination HIV prevention and HIV incidence in Rakai, Uganda. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, WA.
38.
Larmarange  J, Iwuji  C, Orne-Gliemann  J,  et al. Measuring the impact of test and treat on the HIV cascade: the challenge of mobility. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
39.
International AIDS Society.  Differentiated care for HIV: a decision framework for antiretroviral therapy delivery. http://www.differentiatedcare.org/Portals/0/adam/Content/yS6M-GKB5EWs_uTBHk1C1Q/File/Decision%20Framework.pdf. Accessed May 8, 2017.
40.
UNAIDS.  Fast track: ending the AIDS epidemic by 2030. http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. Accessed May 8, 2017.
Original Investigation
June 6, 2017

Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa

Author Affiliations
  • 1School of Public Health, University of California, Berkeley
  • 2University of California, San Francisco
  • 3Harvard T. H. Chan School of Public Health, Boston, Massachusetts
  • 4Infectious Diseases Research Collaboration, Kampala, Uganda
  • 5Kenya Medical Research Institute, Nairobi, Kenya
  • 6Makerere University, Kampala, Uganda
JAMA. 2017;317(21):2196-2206. doi:10.1001/jama.2017.5705
Key Points

Question  Was implementation of a human immunodeficiency virus (HIV) test-and-treat intervention in rural East Africa associated with increases in diagnosis, treatment, and viral suppression among individuals with HIV infection?

Findings  In this study that included 77 774 residents of the intervention communities of an ongoing cluster randomized trial, the proportion of HIV-positive individuals with HIV viral suppression increased from 44.7% at baseline to 80.2% after 2 years, along with increases in HIV diagnosis and initiation of antiretroviral therapy.

Meaning  Implementation of a community-based testing and treatment intervention in East Africa was associated with increased proportion of HIV-positive individuals who achieved viral suppression, along with increased HIV diagnosis and initiation of antiretroviral therapy.

Abstract

Importance  Antiretroviral treatment (ART) is now recommended for all HIV-positive persons. UNAIDS has set global targets to diagnose 90% of HIV-positive individuals, treat 90% of diagnosed individuals with ART, and suppress viral replication among 90% of treated individuals, for a population-level target of 73% of all HIV-positive persons with HIV viral suppression.

Objective  To describe changes in the proportions of HIV-positive individuals with HIV viral suppression, HIV-positive individuals who had received a diagnosis, diagnosed individuals treated with ART, and treated individuals with HIV viral suppression, following implementation of a community-based testing and treatment program in rural East Africa.

Design, Setting, and Participants  Observational analysis based on interim data from 16 rural Kenyan (n = 6) and Ugandan (n = 10) intervention communities in the SEARCH Study, an ongoing cluster randomized trial. Community residents who were 15 years or older (N = 77 774) were followed up for 2 years (2013-2014 to 2015-2016). HIV serostatus and plasma HIV RNA level were measured annually at multidisease health campaigns followed by home-based testing for nonattendees. All HIV-positive individuals were offered ART using a streamlined delivery model designed to reduce structural barriers, improve patient-clinician relationships, and enhance patient knowledge and attitudes about HIV.

Main Outcomes and Measures  Primary outcome was viral suppression (plasma HIV RNA<500 copies/mL) among all HIV-positive individuals, assessed at baseline and after 1 and 2 years. Secondary outcomes included HIV diagnosis, ART among previously diagnosed individuals, and viral suppression among those who had initiated ART.

Results  Among 77 774 residents (male, 45.3%; age 15-24 years, 35.1%), baseline HIV prevalence was 10.3% (7108 of 69 283 residents). The proportion of HIV-positive individuals with HIV viral suppression at baseline was 44.7% (95% CI, 43.5%-45.9%; 3464 of 7745 residents) and after 2 years of intervention was 80.2% (95% CI, 79.1%-81.2%; 5666 of 7068 residents), an increase of 35.5 percentage points (95% CI, 34.4-36.6). After 2 years, 95.9% of HIV-positive individuals had been previously diagnosed (95% CI, 95.3%-96.5%; 6780 of 7068 residents); 93.4% of those previously diagnosed had received ART (95% CI, 92.8%-94.0%; 6334 of 6780 residents); and 89.5% of those treated had achieved HIV viral suppression (95% CI, 88.6%-90.3%; 5666 of 6334 residents).

Conclusions and Relevance  Among individuals with HIV in rural Kenya and Uganda, implementation of community-based testing and treatment was associated with an increased proportion of HIV-positive adults who achieved viral suppression, along with increased HIV diagnosis and initiation of antiretroviral therapy. In these communities, the UNAIDS population-level viral suppression target was exceeded within 2 years after program implementation.

Trial Registration  clinicaltrials.gov Identifier: NCT01864683

×